CA9,CA-IX: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD
It's the GeneMedi's summary page for Target/Biomarker Introduction of CA-IX,CA9. The page also collects GeneMedi's different modalities and formats products for CA-IX in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the CA-IX target is also connected to human indications/diseases/conditions/MOA.
Target sublocation: Transmembrane Protein.
Carbonic anhydrases (CAs) are a large family of zinc metalloenzymes that catalyze the reversible hydration of carbon dioxide. They participate in a variety of biological processes, including respiration, calcification, acid-base balance, bone resorption, and the formation of aqueous humor, cerebrospinal fluid, saliva, and gastric acid. They show extensive diversity in tissue distribution and in their subcellular localization. CA IX is a transmembrane protein and is one of only two tumor-associated carbonic anhydrase isoenzymes known. It is expressed in all clear-cell renal cell carcinoma, but is not detected in normal kidney or most other normal tissues. It may be involved in cell proliferation and transformation. This gene was mapped to 17q21.2 by fluorescence in situ hybridization, however, radiation hybrid mapping localized it to 9p13-p12. [provided by RefSeq, Jun 2014]
|Gene Official Name||CA9|
|Gene Alias||CAIX, MN|
|Protein Sub-location||Transmembrane Protein|
|Category||Therapeutics Target, INN Index, Immuno-oncology Target|
Pre-made CA-IX-specific INN-index biosimilar (antibody&conjugates)-Girentuximab, iodo (124I) girentuximab
Anti-CA-IX therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
|Cat No.||Products Name (INN Index)||INN Name||Previous Name||Target||Format||Order|
|GMP-Bios-ab-245||Pre-Made Girentuximab biosimilar, Whole mAb Radiolabelled, Anti-CA9/CA-IX Antibody: Anti-CAIX/MN therapeutic antibody||Girentuximab||CA9/CA-IX||Whole mAb Radiolabelled|
|GMP-Bios-INN-877||Pre-Made Iodo (124I) Girentuximab Biosimilar, Radiolabelled Antibody, Anti-CA9/CA-IX Antibody: Anti-CAIX/MN therapeutic antibody||iodo (124I) girentuximab||CA9/CA-IX||Radiolabelled antibody|
Pre-made anti-CA-IX inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark reference antibody for drug discovery and mechanism of action (MOA) research
Pre-made anti-CA-IX benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-CA-IX mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
|Cat No.||Antibody Name||Format||Classified by tag||Order|
|GM-Tg-hg-T64567-Ab||Anti-CA-IX/CA9 monoclonal antibody||mab||Biofunctional antibody, Therapeutics Target antibody|